Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.Methods: Case series.Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
Iannetta, M., Cesta, N., Stingone, C., Malagnino, V., Teti, E., Vitale, P., et al. (2020). Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 45, 102442 [10.1016/j.msard.2020.102442].
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
Iannetta, M;Malagnino, V;Teti, E;Di Lorenzo, A;Landi, D;Marfia, GA;Andreoni, M;Sarmati, L
2020-01-01
Abstract
Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.Methods: Case series.Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.| File | Dimensione | Formato | |
|---|---|---|---|
|
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
2.48 MB
Formato
Adobe PDF
|
2.48 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
